Acumen Pharmaceuticals (NASDAQ:ABOS) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS) released its earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.09, FiscalAI reports. The firm had revenue of ($0.09) million during the quarter.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• ALTITUDE-AD readout late 2026 — Acumen expects full efficacy and safety results from its phase II sabirnetug study this year, which the company says will inform its late‑stage development strategy and the broader Aβ‑oligomer hypothesis in AD.
• Preclinical EBD progress and funding — non‑human primate data showed 14–40‑fold higher brain levels for EBD candidates versus native antibody, the profiles exceeded targets, and a recent $35.75 million private placement was raised to advance the program toward an IND targeted in mid‑2027.
• Supportive Phase Ib biomarker signals — in INTERCEPT‑AD sabirnetug produced early CSF improvements (notably phospho‑tau‑181 and neurogranin) after three doses, which management views as supportive for potential phase II efficacy.
• Limited near‑term cash runway and high 2025 losses — year‑end cash and marketable securities of $116.9 million are expected to fund operations only into early 2027, and the company reported a $121.3 million net loss in 2025, implying additional financing will likely be needed to fully execute longer‑term plans.

Acumen Pharmaceuticals Stock Down 11.4%

Shares of NASDAQ:ABOS opened at $2.26 on Friday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. Acumen Pharmaceuticals has a 52-week low of $0.86 and a 52-week high of $3.60. The firm has a market capitalization of $136.89 million, a P/E ratio of -1.12 and a beta of 0.21. The stock has a 50 day moving average price of $2.70 and a 200-day moving average price of $2.16.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research report on Friday, January 9th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of Acumen Pharmaceuticals in a research note on Thursday. Finally, Wall Street Zen lowered shares of Acumen Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Acumen Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $6.67.

Acumen Pharmaceuticals News Summary

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Acumen said it has $36M of funding to advance its EBD program and is targeting an ALTITUDE‑AD Phase II readout in late 2026 — this provides program funding visibility and a clear clinical milestone that could re‑rate shares if results are favorable. Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding
• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set an $8 price target, suggesting sizable upside from current levels and giving institutional validation to the company’s clinical strategy. BTIG buy rating and $8 price target coverage
• Positive Sentiment: Q4 results beat on the EPS line (reported $(0.41) vs. $(0.50) consensus), showing a smaller-than-expected loss and suggesting modest operating leverage as programs advance. Acumen Q4 EPS beat and earnings materials
• Neutral Sentiment: Company press release and earnings‑call highlights outlined strategic advances and program updates (full-year financials and business highlights), which provide context but no immediate new financing or partnership decisions. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full-year 2025 financial report reiterates cash burn, program priorities and R&D focus — useful for modeling runway but not a catalyst by itself. Acumen reports financial results and business highlights
• Negative Sentiment: Acumen filed to sell 10.83 million shares of common stock on behalf of holders — a potential secondary that increases near‑term supply and dilution risk, which likely pressured the stock despite operational positives. Acumen files to sell 10.83M shares for holders

Insider Activity

In related news, CEO Daniel Joseph Oconnell sold 37,755 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $1.99, for a total transaction of $75,132.45. Following the sale, the chief executive officer owned 619,982 shares of the company’s stock, valued at $1,233,764.18. The trade was a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have sold 149,818 shares of company stock valued at $285,057. 9.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. bought a new position in Acumen Pharmaceuticals in the 3rd quarter worth about $27,000. Marshall Wace LLP bought a new stake in Acumen Pharmaceuticals during the 4th quarter valued at about $44,000. OMERS ADMINISTRATION Corp purchased a new position in Acumen Pharmaceuticals in the fourth quarter worth about $47,000. Marex Group plc purchased a new position in Acumen Pharmaceuticals in the second quarter worth about $39,000. Finally, AQR Capital Management LLC bought a new position in shares of Acumen Pharmaceuticals in the first quarter worth approximately $46,000. Institutional investors own 71.01% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.